Cargando…
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
PURPOSE: This analysis evaluated the relationship between treatment-free interval (TFI, in PALOMA-2)/disease-free interval (DFI, in PALOMA-3) and progression-free survival (PFS) and overall survival (OS, in PALOMA-3), treatment effect in patients with bone-only disease, and whether intrinsic subtype...
Autores principales: | Finn, Richard S., Cristofanilli, Massimo, Ettl, Johannes, Gelmon, Karen A., Colleoni, Marco, Giorgetti, Carla, Gauthier, Eric, Liu, Yuan, Lu, Dongrui R., Zhang, Zhe, Bartlett, Cynthia Huang, Slamon, Dennis J., Turner, Nicholas C., Rugo, Hope S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568717/ https://www.ncbi.nlm.nih.gov/pubmed/32783178 http://dx.doi.org/10.1007/s10549-020-05782-4 |
Ejemplares similares
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
por: Zhu, Zhou, et al.
Publicado: (2022) -
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019) -
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
por: Rugo, H S, et al.
Publicado: (2018) -
Overall Survival with Palbociclib and Fulvestrant in Women with HR(+)/HER2(−) ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
por: Cristofanilli, Massimo, et al.
Publicado: (2022) -
Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021)